Tuesday, December 12, 2017
24th Annual Frontiers in Vaccinology: Vaccines, Autism and Blue Marble Health
Tuesday, Dec. 12, 2017, 1 p.m. - 2 p.m., Leadership Hall. Mark your calendar, our speaker for the Center for Vaccine Development's Frontiers in Vaccinology Lectureship is Peter Hotez, MD, PhD, Dean of the National School of Tropical Medicine at Baylor College of Medicine. The event will be held at 1:00 p.m., Leadership Hall (in the MSTF Building)
Monday, November 27, 2017
Analyzing the Impact of a Rotavirus Vaccine in Africa
Diarrheal disease kills one in nine children globally, with the highest mortality in sub-Saharan Africa and South Asia. Karen Kotloff, MD, a pediatric infectious disease specialist at the Center for Vaccine Development (CVD) at the University of Maryland School of Medicine is leading the Vaccine Impact on Diarrhea in Africa (VIDA) study, a follow-on study to the Global Enteric Multicenter Study (GEMS), the largest, most comprehensive study of childhood diarrheal diseases.
Wednesday, November 15, 2017
The Elusive Correlates of Immunity for Diarrheal Diseases
Developing vaccines for bacterial enteric pathogens poses unique challenges; thus, identification of the correlates of immunity (protection) for individual organisms remains a major goal. Diarrheal diseases continue to have a high burden in developing countries and plague the global health community. Researchers from the Massachusetts General Hospital, PATH, Tel Aviv University, and the Center for Vaccine Development at the University of Maryland School of Medicine joined together at ASTMH to share the state of the science on immune responses to cholera, Enterotoxigenic Escherichia coli (ETEC), Shigella, and Salmonella Typhi (S. Typhi).
Wednesday, November 15, 2017
Research Identifies Causes and Possible Treatments for Deadly Diseases Affecting Children in Developing Countries
Each year, more than half a million deaths among children under five years of age around the world are caused by diarrheal diseases – largely due to insufficient access to adequate hygiene, sanitation and clean drinking water. While there are effective preventive measures available, including vaccines, adoption is lagging in low-resource settings where the most severe cases occur.
Friday, September 29, 2017
The “Challenge” of Typhoid Vaccine Development
Forty-seven years ago, Myron M. (“Mike”) Levine, MD, DTPH, the Simon and Bessie Grollman Distinguished Professor and Associate Dean for Global Health, Vaccinology and Infectious Disease, was one of few researchers doing human challenge studies. The University of Maryland typhoid human challenge model established by the late Professor Theodere E. Woodward ran from 1952 to 1974: Data collected contributed to the development of Ty21a, one of two typhoid vaccines currently licensed and recommended by the World Health Organization.
Thursday, September 28, 2017
CVD Director Kathleen Neuzil Appointed to NFID Board
Kathleen M. Neuzil, MD, MPH, FIDSA, Professor of Medicine and Director of the Center for Vaccine Development (CVD) at the University of Maryland School of Medicine (UM SOM), was elected to serve a three-year term to the Board of Directors for the National Foundation for Infectious Diseases (NFID).
Monday, August 07, 2017
UM SOM Scientists Study Antibiotic Impact on Children in Mali with Severe Diarrhea
Researchers from the University of Maryland School of Medicine’s Center for Vaccine Development (CVD) are studying the impact of antibiotic treatment on children from developing countries with severe diarrhea. CVD-Mali is one of seven research centers participating in the study, expected to be complete in 2020.
Monday, August 07, 2017
UM SOM Scientists Learn About Typhoid Burden and Surveillance in Africa
A team of experts from the University of Maryland School of Medicine’s Center for Vaccine Development visited Burkina Faso and Madagascar to learn more about their typhoid surveillance and the burden of typhoid in their countries. The surveillance is currently conducted in collaboration with the International Vaccine Institute (IVI).
Monday, August 07, 2017
UM SOM Scientist Receives NIH Grant for Acinetobacter Baumannii Vaccine Development
The University of Maryland School of Medicine received a one-year bridge grant in the amount of $334,523 from the National Institute of Allergy and Infectious Diseases to continue development of a live bacterial vaccine against Acinetobacter baumannii bacteria, which can lead to lethal pneumonia as well as serious soft tissue infections. The principal investigator for the research is James Galen, PhD, Professor of Medicine and faculty in the Center for Vaccine Development.
Monday, August 07, 2017
Evaluating New Thermostable Rotavirus Vaccine
Experts from the University of Maryland School of Medicine’s Center for Vaccine Development (CVD) are studying the effectiveness and safety of a new enhanced thermostable formulation of a rotavirus vaccine called RotaTeqTM in Mali. The formulation, developed by Merck Sharp & Dohme Corp., is more resistant to temperature fluctuations and packaged in vials with display indicators that signal temperature deviations.